Frank H. Netter, MD School of Medicine, Quinnipiac University, North Haven, CT, USA.
Department of Internal Medicine, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.
Curr Cardiol Rep. 2021 Mar 11;23(5):43. doi: 10.1007/s11886-021-01470-x.
To identify key strengths and weaknesses of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial and explore its clinical implications in patients with stable ischemic heart disease.
Previous studies have shown inconsistent benefit of early angiography and revascularization in patients with stable ischemic heart disease. The ISCHEMIA trial showed no significant reduction in mortality or cardiovascular outcomes in patients undergoing early angiography and revascularization with guideline-directed medical therapy compared to patients on medical therapy alone in specific patient population with stable coronary artery disease. The ISCHEMIA trial provides insights into invasive versus pharmacological treatment for patients with stable ischemic heart disease. Though it may have reduced applicability given its broad exclusion criteria, it offers useful information about the utility of non-invasive imaging modalities for selecting optimal revascularization candidates.
确定国际比较医疗效果与有创治疗稳定性缺血性心脏病研究(ISCHEMIA)试验的主要优缺点,并探讨其在稳定性缺血性心脏病患者中的临床意义。
先前的研究表明,早期血管造影和血运重建对稳定性缺血性心脏病患者的益处并不一致。与单独接受药物治疗的患者相比,ISCHEMIA 试验显示,在具有特定稳定性冠状动脉疾病患者人群中,接受指南指导的药物治疗联合早期血管造影和血运重建的患者死亡率或心血管结局并无显著降低。ISCHEMIA 试验为稳定性缺血性心脏病患者的有创与药物治疗提供了新的见解。虽然鉴于其广泛的排除标准,其适用性可能降低,但它为选择最佳血运重建患者的非侵入性成像方式的实用性提供了有用的信息。